Company Continues Commitment to IPVS Through Sponsorship Activities
MADISON, N.J., May 27, 2016 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) is pleased to announce that it is proud to be a sponsor partner of the 24th International Pig Veterinary Society (IPVS) Congress in Dublin, Ireland, from June 7-10, 2016.
Over the course of four days, the IPVS provides a forum for the swine industry to discuss prevention and treatments of emerging diseases, advances in reproductive technology and arising challenges related to respiratory health.
As part of its commitment, Merck Animal Health will host a satellite symposium on Thursday, June 9, 2016, at 5 p.m., titled, “Building Consumer Trust in the Global Pork Industry –Starts Here.” The symposium will explore the relationship between the swine industry and pork consumers, and how veterinarians can contribute positively to this relationship.
“Merck Animal Health is committed to providing a broad range of solutions to help producers manage swine health and reproduction, and increase operational efficiency,” said Dr. Jan Nemec, Head, Global Swine Business, Merck Animal Health. “We are pleased to share new data about the reproductive lifecycle, as well as the treatment and prevention of some of the most serious diseases affecting pigs.”
Merck Animal Health had several abstracts accepted for oral presentations that cover a broad topic range. Those presentations are as follows:
- Congenital tremor Type A-II in newborn piglets is caused by transplacental transmission of a novel pestivirus (Wednesday, June 8, 10:30 a.m., Hall 2; O-VVD1-002)
- Evaluation of maternally-derived antibodies against Actinobacillus pleuropneumoniae (APP) in piglets from APP-positive herds in Belgium (Thursday, June 9, 3:20 p.m., Hall 2; O-BBD3-011)
- Estimating the costs of Porcine Reproductive and Respiratory Syndrome (PRRS) at individual farm level using a tailor-made mathematical model (Thursday, June 9, 10:30 a.m., Hall 3; O-HHM1-004)
- Impact on fattener performance compared with M hyo only in a PCV2 subclinically infected farm (Friday, June 10, 10:30 a.m., Hall 2; O-IV-003)
- Associations between Ascaris suum infections and different farm management practices (Friday, June 10, 10:30 a.m., Hall 7; O-PA-003)
In addition, the company has an impressive number of studies about scientific advancements made in swine health. The more than 60 posters cover various aspects of Porcine Reproductive and Respiratory Syndrome virus (PRRSv), Porcine Circovirus type 2 (PCV2), IDAL system, diagnostics and reproductive performance.
For more information about the 24th International Pig Veterinary Society (IPVS) Congress, visit http://www.ipvs2016.com/. Learn more about Merck Animal Health’s swine respiratory and reproduction management systems by visiting the web. For more information about MSD Animal Health, visit the company’s website.
About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn or Facebook and Twitter .
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ).